WO2021147846A1 - 抗btla抗体药物组合物及其用途 - Google Patents
抗btla抗体药物组合物及其用途 Download PDFInfo
- Publication number
- WO2021147846A1 WO2021147846A1 PCT/CN2021/072660 CN2021072660W WO2021147846A1 WO 2021147846 A1 WO2021147846 A1 WO 2021147846A1 CN 2021072660 W CN2021072660 W CN 2021072660W WO 2021147846 A1 WO2021147846 A1 WO 2021147846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- buffer
- sodium chloride
- antibody
- histidine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 74
- 239000003381 stabilizer Substances 0.000 claims abstract description 73
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims abstract description 38
- 239000004094 surface-active agent Substances 0.000 claims abstract description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 204
- 239000000872 buffer Substances 0.000 claims description 115
- 239000011780 sodium chloride Substances 0.000 claims description 102
- 230000027455 binding Effects 0.000 claims description 96
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 63
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 57
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 57
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 39
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 39
- 229920000053 polysorbate 80 Polymers 0.000 claims description 39
- 229940068968 polysorbate 80 Drugs 0.000 claims description 39
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 38
- 229930195725 Mannitol Natural products 0.000 claims description 38
- 239000000594 mannitol Substances 0.000 claims description 38
- 235000010355 mannitol Nutrition 0.000 claims description 38
- 239000005720 sucrose Substances 0.000 claims description 36
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 34
- 229930006000 Sucrose Natural products 0.000 claims description 34
- 239000000600 sorbitol Substances 0.000 claims description 34
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 31
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical group Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 239000008351 acetate buffer Substances 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 239000007979 citrate buffer Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 229940068977 polysorbate 20 Drugs 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 125000000647 trehalose group Chemical group 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000000185 sucrose group Chemical group 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006143 Brain stem glioma Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010037394 Pulmonary haemorrhage Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 208000019629 polyneuritis Diseases 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000011294 ureter cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 abstract description 37
- 239000007853 buffer solution Substances 0.000 abstract description 15
- 235000002639 sodium chloride Nutrition 0.000 description 89
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 82
- 229960002885 histidine Drugs 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 44
- 238000009472 formulation Methods 0.000 description 28
- 150000001413 amino acids Chemical group 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000000670 limiting effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- -1 ICOS Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 239000012669 liquid formulation Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 7
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- QAWLKTDBUQOFEF-UHFFFAOYSA-N 3-(4-bromophenyl)propanenitrile Chemical compound BrC1=CC=C(CCC#N)C=C1 QAWLKTDBUQOFEF-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 102000053464 human BTLA Human genes 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000012931 lyophilized formulation Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical group [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical group [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000033300 receptor internalization Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- ABGZKEOYRQFMCR-OXIHULNRSA-M sodium;(2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ABGZKEOYRQFMCR-OXIHULNRSA-M 0.000 description 2
- ABGZKEOYRQFMCR-MGXNYLRYSA-M sodium;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;chloride Chemical compound [Na+].[Cl-].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ABGZKEOYRQFMCR-MGXNYLRYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- HHNJQTAVFGQHBP-UHFFFAOYSA-L C(C)(=O)O.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] Chemical compound C(C)(=O)O.C(C)(=O)[O-].[Mg+2].C(C)(=O)[O-] HHNJQTAVFGQHBP-UHFFFAOYSA-L 0.000 description 1
- BMCZJPYYEFQOCO-UHFFFAOYSA-H C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Mg+2].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Mg+2].[Mg+2] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Mg+2].C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Mg+2].[Mg+2] BMCZJPYYEFQOCO-UHFFFAOYSA-H 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- XYUPSBLFPTWJLC-GSVOUGTGSA-N N-(carboxymethyl)-D-alanine Chemical compound OC(=O)[C@@H](C)NCC(O)=O XYUPSBLFPTWJLC-GSVOUGTGSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- DGPUYHMCOANORE-UHFFFAOYSA-L calcium;acetic acid;diacetate Chemical compound [Ca+2].CC(O)=O.CC([O-])=O.CC([O-])=O DGPUYHMCOANORE-UHFFFAOYSA-L 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012927 reference suspension Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 108700022952 strombine Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- SYSWJPSVYLUKCH-UHFFFAOYSA-H tricalcium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca+2].[Ca+2].[Ca+2].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SYSWJPSVYLUKCH-UHFFFAOYSA-H 0.000 description 1
- SPRBJFWIUVWXBT-UHFFFAOYSA-K tripotassium 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SPRBJFWIUVWXBT-UHFFFAOYSA-K 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of therapeutic pharmaceutical compositions.
- the present invention relates to the field of pharmaceutical preparations.
- the pharmaceutical composition contains a humanized antibody that specifically binds to B and T lymphocyte attenuator (BTLA).
- BTLA B and T lymphocyte attenuator
- T cell receptors TCR
- TCR T cell receptors
- the prototype T cell costimulatory molecule CD28 When interacting with B7.1 or B7.2 on the surface of antigen presenting cells (APC), the prototype T cell costimulatory molecule CD28 sends out signals that promote T cell proliferation and differentiation in response to the participation of TCR, but the CD28 homolog is cytotoxic T Lymphocyte antigen-4 (CTLA-4) mediates the inhibition of T cell proliferation and effector functions (Chambers et al., Ann. Rev. Immunol., 19:565-594, 2001; Egen et al., Nature Immunol, 3:611- 618, 2002).
- CTLA-4 cytotoxic T Lymphocyte antigen-4
- B and T lymphocyte attenuators are members of the CD28 family, which also includes CD28, ICOS, CTLA-4 and PD-1. According to the functional effect of the addition of monoclonal antibodies on improving the proliferation of T cells, it was found that CD28 and ICOS, the first members of the family, have immune activation effects (Hutloff et al., 1999). And BTLA, CTLA-4 and PD-1 are described as negative regulatory proteins. Several in vivo studies have confirmed the inhibitory effect of BTLA in lymphocyte response. BTLA-deficient mice prepared by Murphy and colleagues (Washington University St. Louis) showed a 3-fold increase in IgG production in response to T-dependent antigens.
- T cells and B cells isolated from BTLA- mouse showed greater proliferative responses to antigen-receptor stimulation using CD3- and anti-IgM, respectively (Watanabe, 2003).
- BTLA was found to associate with B cell receptor complexes and with T cell receptors. Consistent with the results of this study, in BTLA-deficient lymphocytes, the use of ConA (T cells) or LPS (B cells) for antigen-receptor independent stimulation is not affected, and the use of anti-BTLA antibodies cannot be regulated.
- T cells ConA
- B cells LPS
- BTLA knockout mice develop spontaneous autoimmune diseases over time and shorten their lifespan (Oya, 2008).
- BTLA knockout mice showed increased disease severity in autoimmune encephalomyelitis (EAE) and allergic airway inflammation models, both of which depend on T cell activity (Watanabe, 2005; Deppong, 2006).
- HVEM herpes virus entry mediator
- BTLA a ligand for BTLA
- CDRs extracellular cysteine-rich regions
- BTLA and HVEM mainly regulate the functions of T cells and APC through dynamic expression on the cell surface.
- the combination of BTLA and ligand not only inhibits T cell proliferation, down-regulates T cell activation marker CD25, but also inhibits the production of IFN- ⁇ , IL-2, IL-4, and IL-10, but cannot induce cell apoptosis.
- Antibodies can be used as therapeutic drugs. Certain antibodies can cause unwanted antibody immunogenicity when used as therapeutic drugs in the body. Because most monoclonal antibodies are derived from rodents, repeated use in humans results in an immune response against therapeutic antibodies (for example, human anti-mouse antibodies or HAMA). This type of immune response leads at least to the loss of therapeutic efficacy, and at the highest to potentially lethal allergic reactions.
- One method of reducing the immunogenicity of rodent antibodies involves the production of chimeric antibodies, in which the mouse variable region (Fv) is fused with the human constant region (Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84 : 3439-43). However, mice injected with a hybrid of human variable region and mouse constant region developed a strong antibody response against the human variable region, which indicates that the retention of the complete rodent Fv region in this chimeric antibody can still be used in patients. Causes harmful immunogenicity in.
- CDR loops of rodent variable domains onto human frameworks have been used to further minimize rodent sequences. Jones et al. (1986) Nature 321:522; Verhoeyen et al. (1988) Science 239:1534.
- CDR loop exchange still cannot uniformly produce antibodies with the same binding properties as the starting antibody.
- FR framework residues
- sequences of known antibodies are already being used, or more commonly the sequences of antibodies with known X-ray crystal structures such as antibodies NEW and KOL are used. See, for example, Jones et al., supra; Verhoeyen et al., supra; and Gorman et al., supra. The exact sequence information of a few humanized constructs has been reported.
- anti-BTLA antibodies particularly anti-BTLA monoclonal antibodies
- human disorders such as inflammatory disorders, autoimmune disorders, and proliferative disorders.
- Such antibodies may preferably have low immunogenicity in human subjects, allowing repeated administration without adverse immune responses.
- the pharmaceutical composition of the present invention is a highly stable pharmaceutical composition containing human antibodies specifically binding to BTLA.
- the present invention found that the combination of trehalose and sodium chloride can significantly improve the stability of the pharmaceutical composition.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising: (1) a buffer; and (2) an anti-BTLA antibody or an antigen-binding fragment thereof.
- the above-mentioned anti-BTLA antibody or antigen-binding fragment thereof has an amino acid sequence of HCDR1, HCDR2, and HCDR3 shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and an amino acid sequence of HCDR1, HCDR2, and HCDR3, respectively, as shown in The LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
- the concentration of the anti-BTLA antibody or antigen-binding fragment thereof in the pharmaceutical composition is about 1-200 mg/mL, preferably about 5-100 mg/mL, preferably about 10-50 mg/mL; more preferably The concentration of the aforementioned anti-BTLA antibody or its antigen-binding fragment is about 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 35 mg/mL, 40 mg/mL, 45 mg/mL or 50 mg/mL, preferably about 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 35 mg/mL, 40 mg/mL, 45 mg/mL or 50 mg/mL It is 10mg/mL, 20mg/mL, 40mg/mL.
- the above-mentioned buffer is selected from one or more of acetate buffer, citrate buffer, and histidine buffer.
- the above-mentioned buffer is a histidine buffer, preferably, the histidine buffer is selected from histidine-hydrochloride buffer or histidine-acetate buffer, preferably histidine Acid-hydrochloride buffer.
- the aforementioned histidine-hydrochloride buffer is composed of histidine and histidine hydrochloride, preferably L-histidine and L-histidine monohydrochloride.
- the histidine buffer is made of 1-20 mM L-histidine and 1-20 mM L-histidine monohydrochloride.
- the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:1 to 1:4.
- the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:1.
- the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:3.
- the histidine preparation is: a histidine buffer with a pH of 5.5 made of 4.5 mM L-histidine and 15.5 mM L-histidine monohydrochloride.
- the histidine preparation is: a histidine buffer with a pH of 6.0 made of 15 mM histidine and 15 mM histidine hydrochloride.
- the above-mentioned histidine buffer is a histidine-acetate buffer, preferably, the molar ratio of the two is 1:1 to 1.5:1, and preferably, the pH of such a buffer is 5.5 ⁇ 0.3 , Preferably about 5.5, preferably, this kind of buffer contains 15-20 mM histidine and 12-15 mM acetic acid.
- the above-mentioned buffer is an acetate buffer.
- the acetate buffer is an acetic acid-sodium acetate buffer or an acetic acid-potassium acetate buffer, preferably an acetic acid-sodium acetate buffer.
- the above-mentioned buffer is a citric acid buffer, and preferably, the citric acid buffer is a citric acid-sodium citrate buffer.
- the concentration of the above-mentioned buffer is about 1-100 mM, preferably about 5-50 mM, preferably about 10-30 mM, preferably about 20-30 mM; preferably about 10-20 mM, and the above-mentioned buffer concentration is not limited Typical examples are about 5mM, 10mM, 15mM, 20mM, 25mM, 30mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM, 80mM, 85mM, 90mM, 95mM or 100mM or any two values in these ranges
- the range formed by the end point is preferably 10 mM, 20 mM, or 30 mM.
- the pH of the aforementioned buffer is about 5.0-6.5, preferably about 5.0-6.0, preferably about 5.5-6.5, preferably about 5.0-5.5, preferably about 5.5-6.0, preferably about 6.0-6.5 ,
- a non-limiting example of the pH of the above buffer is about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, preferably about 5.0, 5.5 or 6.0.
- the aforementioned pharmaceutical composition further includes a stabilizer selected from one or more of sodium chloride, mannitol, sorbitol, sucrose, maltose, xylitol, and trehalose.
- a stabilizer selected from one or more of sodium chloride, mannitol, sorbitol, sucrose, maltose, xylitol, and trehalose.
- the stabilizer is a combination of trehalose and sodium chloride.
- the concentration of the aforementioned stabilizer is about 20 mM to 300 mM, preferably 50 mM to 300 mM, more preferably 120 mM to 250 mM.
- the stabilizer is sodium chloride at a concentration of about 50-200 mM; or the stabilizer is mannitol at a concentration of about 100-300 mM; or the stabilizer is sorbitol at a concentration of about 100-300 mM; or The stabilizer is sucrose with a concentration of about 100-300mM; or the stabilizer is trehalose with a concentration of about 100-300mM; or the stabilizer is about 30-100mM sodium chloride and about 50-200mM mannitol
- the stabilizer is a combination of about 30-100mM sodium chloride and about 50-200mM sorbitol; the stabilizer is a combination of about 30-100mM sodium chloride and about 50-200mM sucrose;
- the stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM trehalose.
- the aforementioned stabilizer is sodium chloride.
- the aforementioned stabilizer is sodium chloride at a concentration of about 50-200 mM, and the concentration of the aforementioned sodium chloride is preferably about 100-190 mM, preferably about 120-180 mM, preferably about 130-170 mM, preferably about 130. -150mM, non-limiting examples of the above sodium chloride concentration are about 100mM, 110mM, 120mM, 125mM, 130mM, 135mM, 140mM, 145mM, 150mM, 155mM, 160mM, 170mM, 180mM, 190mM, 200mM, preferably 135mM or 140mM .
- the aforementioned stabilizer is mannitol.
- the aforementioned stabilizer is mannitol at a concentration of about 100-300 mM, the concentration of the aforementioned mannitol is preferably about 150-300 mM, preferably about 200-280 mM, and a non-limiting example of the aforementioned mannitol concentration is about 200 mM. , 210mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM, 280mM, preferably 240mM.
- the aforementioned stabilizer is sorbitol.
- the aforementioned stabilizer is sorbitol at a concentration of about 100-300 mM, the concentration of the aforementioned sorbitol is preferably about 150-300 mM, preferably about 200-280 mM, and a non-limiting example of the aforementioned sorbitol concentration is about 200 mM. , 210mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM, 280mM, preferably 240mM.
- the aforementioned stabilizer is sucrose. In some embodiments, the aforementioned stabilizer is sucrose at a concentration of about 100-300 mM. The concentration of the aforementioned sucrose is preferably about 150-300 mM, preferably about 200-280 mM. A non-limiting example of the aforementioned sucrose concentration is about 200 mM, 210 mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM, 280mM, preferably 220mM.
- the aforementioned stabilizer is trehalose.
- the aforementioned stabilizer is trehalose with a concentration of about 100-300 mM.
- the concentration of the aforementioned trehalose is preferably about 150-300 mM, preferably about 200-280 mM.
- a non-limiting example of the aforementioned trehalose concentration is about 180mM, 200mM, 210mM, 220mM, 230mM, 240mM, 250mM, 260mM, 270mM, 280mM, preferably 220mM.
- the aforementioned stabilizer is a combination of sodium chloride and mannitol. In some aspects, the aforementioned stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM mannitol, preferably a combination of about 40-80 mM sodium chloride and about 100-180 mM mannitol, preferably about A combination of 40-60 mM sodium chloride and about 120-160 mM mannitol, a non-limiting example of the above stabilizer is a combination of about 54 mM sodium chloride and about 144 mM mannitol, and about 50 mM sodium chloride and A combination of about 140 mM mannitol.
- the aforementioned stabilizer is a combination of sodium chloride and sorbitol. In some aspects, the aforementioned stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM sorbitol, preferably a combination of about 40-80 mM sodium chloride and about 100-180 mM sorbitol, preferably about A combination of 40-60 mM sodium chloride and about 120-160 mM sorbitol, a non-limiting example of the above stabilizer is a combination of about 54 mM sodium chloride and about 144 mM sorbitol, and about 40 mM sodium chloride and A combination of about 160 mM sorbitol.
- the aforementioned stabilizer is a combination of sodium chloride and sucrose. In some aspects, the aforementioned stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM sucrose, preferably a combination of about 40-80 mM sodium chloride and about 100-180 mM sucrose, preferably about 40-180 mM sodium chloride.
- a combination of 60 mM sodium chloride and about 120-160 mM sucrose, a non-limiting example of the above stabilizer is a combination of about 54 mM sodium chloride and about 132 mM sucrose, about 50 mM sodium chloride and about 150 mM sucrose The combination.
- the aforementioned stabilizer is a combination of sodium chloride and trehalose.
- the aforementioned stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM trehalose, preferably a combination of about 40-80 mM sodium chloride and about 100-180 mM trehalose, preferably about A combination of 40-60 mM sodium chloride and about 120-160 mM trehalose, a non-limiting example of the above stabilizer is a combination of about 54 mM sodium chloride and about 132 mM trehalose, and about 50 mM sodium chloride and A combination of about 140mM trehalose, a combination of about 60mM sodium chloride and about 120mM trehalose, preferably a combination of about 54mM sodium chloride and about 132mM trehalose, or a combination of about 50mM sodium chloride and about 140mM The combination of trehalose.
- the above-mentioned pharmaceutical composition further includes a surfactant, and the surfactant is selected from polysorbate 80, polysorbate 20, or poloxamer 188.
- the above-mentioned surfactant is selected from polysorbate 80.
- the above-mentioned surfactant is selected from polysorbate 20.
- the concentration of the above-mentioned surfactant is about 0.001%-0.1%, preferably about 0.01%-0.05%, preferably about 0.02%-0.04%; as a non-limiting example, the above-mentioned surfactant concentration
- the concentration of the surfactant is about 0.02%, 0.03% or 0.04%, preferably 0.02%.
- the aforementioned anti-BTLA antibody or antigen-binding fragment thereof is selected from murine antibodies, chimeric antibodies, and humanized antibodies, preferably humanized antibodies.
- the aforementioned anti-BTLA antibody or antigen-binding fragment thereof has a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 8.
- the above-mentioned anti-BTLA antibody or antigen-binding fragment thereof has a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 9.
- the aforementioned anti-BTLA antibody or antigen-binding fragment thereof has a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 10.
- the aforementioned anti-BTLA antibody or antigen-binding fragment thereof has a heavy chain amino acid sequence as shown in SEQ ID NO: 11 and a light chain amino acid sequence as shown in SEQ ID NO: 12.
- the above-mentioned pharmaceutical composition comprises the components shown in any one of the following (1)-(8), or consists of the components shown in any one of the following (1)-(8); wherein
- the anti-BTLA antibody or antigen-binding fragment thereof is as described in any of the embodiments of the present invention:
- the above-mentioned pharmaceutical composition comprises the components shown in any one of the following (9)-(13), or consists of the components shown in any one of the following (9)-(13);
- the pharmaceutical composition is a liquid formulation or a lyophilized formulation.
- the pharmaceutical composition is a liquid formulation, such as an aqueous formulation.
- the above-mentioned liquid formulation or lyophilized formulation is stable at 2-8°C for at least 3 months, at least 6 months, at least 12 months, at least 18 months, or at least 24 months.
- the above-mentioned aqueous solution or lyophilized formulation is stable at 40°C for at least 7 days, at least 14 days, or at least 28 days.
- the present invention also provides the use of the above-mentioned pharmaceutical composition in the preparation of a medicine for treating or preventing BTLA-mediated diseases.
- the aforementioned diseases include tumors, infectious diseases, inflammatory or autoimmune diseases.
- the tumors include melanoma, breast cancer, kidney cancer, prostate cancer, colon cancer, lung cancer, pancreatic cancer, bone cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer , Testicular cancer, esophageal cancer, small intestine cancer, cervical cancer, vaginal cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, endocrine system cancer, thyroid cancer, adrenal glands, soft tissue cancer, urethral cancer, chronic Or acute leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal pelvis cancer, neoplasms of the central nervous system Biology, primary central nervous system lymphoma, tumor an
- the autoimmune diseases include organ-specific autoimmune diseases and systemic autoimmune diseases;
- the organ-specific autoimmune diseases include chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, and ulcers Colitis, pernicious anemia with chronic atrophic gastritis, pulmonary hemorrhage nephritis syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple cerebrospinal sclerosis, acute idiopathic polyneuritis Etc.
- the systemic autoimmune diseases include systemic lupus erythematosus, subhumid arthritis, systemic vasculitis, scleroderma, gastrocnemius, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia , Ulcerative colitis, etc.
- Figure 1 Comparative experiment of the binding of humanized antibody hu 17 with different species of BTLA.
- Figure 2 The effect of hu18 on the tumor volume of B-hBTLA mice transplanted with MC38-hHVEM cells.
- Figure 3 The effect of the test substance on the body weight of B-hBTLA mice transplanted with MC38-hHVEM cells.
- pharmaceutical composition or “preparation” means a mixture containing one or more of the compounds described herein or their pharmaceutically acceptable salts or prodrugs and other components, such as physiologically pharmaceutically acceptable Carriers and excipients.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and thus the biological activity.
- liquid formulation refers to a formulation in a liquid state, and is not intended to refer to a lyophilized formulation that is resuspended.
- the liquid formulation of the present invention is stable during storage, and its stability does not depend on lyophilization (or other state change methods, such as spray drying).
- aqueous liquid preparation refers to a liquid preparation using water as a solvent.
- the aqueous liquid formulation is a formulation that does not require lyophilization, spray drying, and/or freezing to maintain stability (e.g., chemical and/or physical stability and/or biological activity).
- excipient refers to an agent that can be added to a formulation to provide desired characteristics (e.g., consistency, increased stability) and/or to adjust osmotic pressure.
- desired characteristics e.g., consistency, increased stability
- excipients include, but are not limited to, sugars, polyols, amino acids, surfactants, and polymers.
- the "about” used in this application when referring to a measurable value is intended to cover a variation of ⁇ 20% or ⁇ 10% relative to a specific value, including ⁇ 5%, ⁇ 1%, and ⁇ 0.1 %, because these changes are suitable for carrying out the disclosed method.
- buffer pH is about 5.0-6.5
- the buffer used in the formulation of the present invention may have a pH in the range of about 5.0 to about 6.5, or a pH in the range of about 5.5 to about 6.5, or a pH in the range of about 5.0 to about 6.0.
- examples of the "buffer” for controlling the pH within this range include acetate (such as sodium acetate), succinate (such as sodium succinate), gluconic acid, histidine, histidine hydrochloride , Methionine, citrate, phosphate, citrate/phosphate, imidazole, acetic acid, acetate, citrate, combinations thereof and other organic acid buffers.
- Hetidine buffer is a buffer containing histidine ions.
- histidine buffers include histidine and histidine salts, such as histidine hydrochloride, histidine acetate, histidine phosphate and histidine sulfate, etc., such as containing histidine
- the histidine buffer solution of acid and histidine hydrochloride; the histidine buffer solution of the present invention also includes histidine buffer solution containing histidine and acetate (such as sodium salt or potassium salt).
- citrate buffer is a buffer that includes citrate ions.
- citrate buffers include citric acid-sodium citrate, citric acid-potassium citrate, citric acid-calcium citrate, citric acid-magnesium citrate, and the like.
- the preferred citrate buffer is citric acid-sodium citrate buffer.
- Acetate buffer is a buffer that includes acetate ions.
- acetate buffers include acetic acid-sodium acetate, acetic acid-potassium acetate, acetic acid-calcium acetate, acetic acid-magnesium acetate, and the like.
- the preferred acetate buffer is acetic acid-sodium acetate buffer.
- stabilizer means a pharmaceutically acceptable excipient that protects the active pharmaceutical ingredient and/or formulation from chemical and/or physical degradation during manufacture, storage and application.
- Stabilizers include, but are not limited to, sugars, amino acids, salts, polyols and their metabolites as defined below, such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, trehalose, arginine hydrochloride, Arginine, glycine, alanine ( ⁇ -alanine, ⁇ -alanine), betaine, leucine, lysine, glutamic acid, aspartic acid, proline, 4-hydroxy Proline, sarcosine, ⁇ -aminobutyric acid (GABA), opines, alanine, octopine, glycinine (strombine) and trimethylamine N-oxide (TMAO) , Human serum albumin (hsa), bovine serum albumin (bsa), and tri
- Some stabilizers such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, etc. can also play a role in controlling osmotic pressure.
- the stabilizer specifically used in the present invention is selected from one or two or more of polyols, salts, and sugars.
- the preferred salt is sodium chloride
- the preferred sugars are sucrose and trehalose
- the preferred polyols are sorbitol and mannitol.
- Preferred stabilizers are sodium chloride, mannitol, sorbitol, sucrose, trehalose, sodium chloride-sorbitol, sodium chloride-mannitol, sodium chloride-sucrose and sodium chloride-trehalose, more preferably Sodium chloride-sorbitol, sodium chloride-mannitol, sodium chloride-sucrose and sodium chloride-trehalose, more preferably sodium chloride-trehalose.
- surfactant generally includes agents that protect proteins, such as antibodies, from stress induced by the air/solution interface, solution/surface-induced stress to reduce antibody aggregation or minimize the formation of particulates in the formulation.
- exemplary surfactants include, but are not limited to, nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters (such as polysorbate 20 and polysorbate 80), polyethylene-polypropylene copolymers, poly Ethylene-polypropylene glycol, polyoxyethylene-stearate, polyoxyethylene alkyl ether, such as polyoxyethylene monolauryl ether, alkylphenyl polyoxyethylene ether (Triton-X), polyoxyethylene- Polyoxypropylene copolymer (Pluronic), sodium dodecyl sulfate (SDS).
- nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters (such as polysorbate 20 and polysorbate 80), polyethylene-polypropylene copolymers,
- isotonic means that the preparation has substantially the same osmotic pressure as human blood. Isotonic formulations generally have an osmotic pressure of about 250 to 350 mOsm. The isotonicity can be measured using a vapor pressure or freezing point drop osmometer.
- stable formulation is a formulation in which the antibody substantially maintains its physical stability and/or chemical stability and/or biological activity during the manufacturing process and/or during storage. Even if the contained antibody fails to maintain 100% of its chemical structure or biological function after a certain period of storage, the pharmaceutical preparation can be stable. In some cases, after a certain period of storage, it can maintain about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the structure or function of the antibody, which can also be considered as " stable”.
- Various analytical techniques for measuring protein stability are available in this technical field and are reviewed in "Peptide and Protein Drug Delivery” 247-301, Vincent Lee, Editor-in-Chief, Marcel Dekker, Inc. ., New York, NY, Pubs. (1991)), and Jones, A. (1993) Adv. Drug Delivery Rev. 10: 29-90 (both are incorporated by reference).
- the stability of the protein is determined by the percentage of monomeric protein in a solution that has a low percentage of degradation (eg, fragmentation) and/or aggregated protein.
- the formulation can be stored stably at room temperature, about 25-30°C, or 40°C for at least 2 weeks, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months, or Longer, no more than about 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% antibody in aggregate form at most.
- an acceptable degree of stability means that when the formulation is stored at a certain temperature for a certain period of time, the acidic form of the antibody that can be detected therein does not exceed about 49%, 45%, 40%, 35.
- the certain period of storage before measuring stability can be at least 2 weeks, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months, or longer.
- a certain temperature that allows the storage of the pharmaceutical preparation can be any temperature in the range of about -80°C to about 45°C, for example, storage at about -80°C, about -30°C, about -20°C, or about 0°C , About 2-8°C, about 5°C, about 25°C, or about 40°C.
- the antibody does not substantially show signs of aggregation, precipitation, and/or denaturation during visual inspection of color and/or clarity or by UV light scattering or measurement by pore exclusion chromatography, the antibody is in the drug combination
- the substance "maintains its physical stability”. Aggregation is the process by which single molecules or complexes associate covalently or non-covalently to form aggregates. Aggregation can proceed to the point where visible precipitates are formed.
- the stability of the formulation can be evaluated by methods known in the art, including measuring the apparent extinction (absorbance or optical density) of the sample. Such extinction measurement is related to the turbidity of the formulation.
- the turbidity of a formulation is partly an inherent property of the protein dissolved in the solution, and is usually measured by turbidimetric method and measured in turbidimetric turbidity units (NTU).
- the level of turbidity that varies with, for example, the concentration of one or more components in the solution (eg, protein and/or salt concentration) is also referred to as the "opaqueness" or “opaque appearance" of the formulation.
- the turbidity level can be calculated with reference to a standard curve generated using a suspension of known turbidity.
- the reference standard used to determine the turbidity level of the pharmaceutical composition can be based on the "European Pharmacopoeia” standard ("European Pharmacopoeia”, fourth edition, "Directorate for the Quality of Medicine” of the Council of Europe (EDQM), France).
- a clear solution is defined as a solution with a turbidity lower than or equal to the turbidity of a reference suspension of about 3 according to the "European Pharmacopoeia” standard.
- Turbidity measurement by turbidimetry can detect Rayleigh scattering in the absence of association or non-ideal effects, which usually varies linearly with concentration. Other methods for assessing physical stability are well known in the art.
- the antibody "retains its chemical stability" in the pharmaceutical composition.
- the chemical stability can be assessed by, for example, detecting or quantifying the form of the chemical change of the antibody.
- Chemical changes can include size changes (e.g., cropping), which can be assessed using, for example, size exclusion chromatography, SDS-PAGE, and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS).
- Other types of chemical changes include charge changes (for example, occurring as a result of deamidation or oxidation), which can be assessed by, for example, ion exchange chromatography.
- the antibody in the pharmaceutical composition is biologically active for its intended purpose, the antibody "retains its biological activity" in the pharmaceutical composition.
- the binding affinity of the anti-BTLA antibody contained in the preparation to BTLA is the binding affinity of the antibody before the storage At least 90%, 95% or more of the content, the formulation of the present invention can be considered to be stable.
- the binding affinity can also be determined using techniques such as ELISA or plasmon resonance.
- the "therapeutically effective amount” or “effective amount” of the antibody refers to an amount effective in the prevention or treatment or alleviation of symptoms of disorders that the antibody can effectively treat.
- the "therapeutically effective dose” or “therapeutically effective dose” of the drug is any amount of drug that protects the subject from the onset of disease or promotes the regression of the disease when used alone or in combination with another therapeutic agent. The regression of the disease is evidenced by a reduction in the severity of the symptoms of the disease, an increase in the frequency and duration of the asymptomatic period of the disease, or the prevention of injury or disability caused by the pain of the disease.
- a therapeutically effective amount of a drug includes a "prophylactically effective amount", that is, any amount that inhibits the development or recurrence of the disease when administered to a subject at risk of disease or a subject who has relapsed, alone or in combination with other therapeutic drugs medicine.
- subject or "patient” is intended to include mammalian organisms.
- subjects/patients include humans and non-human mammals, such as non-human primates, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
- the subject is a human.
- Anti-PD-1 antibody administration routes include intravenous, intramuscular, subcutaneous, peritoneal, spinal, or other parenteral administration routes, such as injection or infusion.
- Parenteral administration refers to administration methods usually by injection other than enteral or local administration, including but not limited to intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, and intrasaccular , Intra-frame, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspine, intradural and intrasternal injection and infusion, and intracorporeal electroporation.
- antibody as used herein should be understood to include intact antibody molecules and antigen-binding fragments thereof.
- antigen-binding portion or “antigen-binding fragment” (or simply “antibody portion” or “antibody fragment") of an antibody refers to the antibody that retains human BTLA (B and T lymphocyte attenuator) or One or more fragments of its epitope-specific binding ability.
- full-length antibody or “complete antibody molecule” as used herein refers to an immunoglobulin molecule comprising four peptide chains, two heavy (H) chains (about 50-70kDa at full length) and two light (L) chains (Approximately 25kDa at full length) are connected to each other by disulfide bonds.
- Each heavy chain is composed of a heavy chain variable region (abbreviated as VH herein) and a heavy chain constant region (abbreviated as CH herein).
- the heavy chain constant region is composed of three structural domains CH1, CH2 and CH3.
- Each light chain is composed of a light chain variable region (abbreviated as VL herein) and a light chain constant region.
- the light chain constant region consists of a domain CL.
- VH and VL regions can be further subdivided into complementarity determining regions (CDR) with high variability and more conservatively spaced regions called framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each VH or VL region consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxy terminus.
- the variable regions of the heavy and light chains contain binding domains that interact with antigens.
- the constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors (including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system).
- CDR refers to the complementarity determining region within the variable sequence of an antibody.
- HCDR1, HCDR2, and HCDR3 or LCDR1, LCDR2, and LCDR3 are 3 CDRs in each variable region of the heavy chain and light chain.
- the precise boundaries of these CDRs have different definitions according to different systems.
- variable region CDRs of the antibodies of the present invention can be determined using any of many well-known schemes, including Chothia based on the three-dimensional structure of the antibody and the topology of the CDR loops (Chothia et al.
- antigen-binding fragment includes fragments of antibodies or derivatives thereof, usually including at least one fragment of the antigen-binding region or variable region (eg, one or more CDRs) of the parent antibody, which retains at least some of the parent antibody Binding specificity.
- antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, such as sc-Fv; nanobodies formed from antibody fragments And multispecific antibodies.
- the binding fragment or derivative thereof When the binding activity of an antibody is expressed on a molar concentration basis, the binding fragment or derivative thereof generally retains at least 10% of the antigen binding activity of the parent antibody.
- the binding fragment or derivative thereof retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the antigen binding affinity of the parent antibody. It is also expected that the antigen-binding fragment of an antibody may include conservative or non-conservative amino acid substitutions that do not significantly change its biological activity (referred to as “conservative variants” or “functionally conservative variants” of the antibody).
- the anti-BTLA antibody or antigen-binding fragment thereof of the present invention includes any one of the anti-BTLA antibodies described in the application number CN201810870514.0, and the entire content disclosed herein is incorporated herein by way of introduction.
- the CDR sequences of the antibodies used in the methods and compositions of the present invention include the CDR sequences from the antibody hu18 described in CN201810870514.0.
- the CDR sequences of the antibodies used in the methods and compositions of the present invention include the CDR sequences from the antibody hu17 described in CN201810870514.0.
- the CDR sequences of the antibodies used in the methods and compositions of the present invention include the CDR sequences from the antibody hu19 described in CN201810870514.0.
- the non-limiting and exemplary antibodies used in the examples herein are selected from the hu17, hu18, and hu19 described in CN201810870514.0, all of which are fully humanized antibodies that specifically bind to human BTLA, wherein the antibodies hu17, hu18 and hu19 has amino acid sequences such as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, HCDR1, HCDR2 and HCDR3, and amino acid sequences such as SEQ ID NO: 4, SEQ ID NO: 5 and The LCDR1, LCDR2, and LCDR3 shown in SEQ ID NO: 6; preferably, the antibody hu17 has a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7 and an amino acid sequence as shown in SEQ ID NO: 8 The variable region of the chain; antibody hu18 has the amino acid sequence of the heavy chain variable region shown in SEQ ID NO: 7 and the amino acid sequence of the light chain variable region shown in SEQ ID NO: 9; antibody
- the pharmaceutical composition of the present invention is a highly stable pharmaceutical composition containing human antibodies specifically binding to BTLA.
- the present invention found that the combination of trehalose and sodium chloride can significantly improve the stability of the pharmaceutical composition.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising: (1) a buffer; and (2) an anti-BTLA antibody or an antigen-binding fragment thereof.
- the antibody in the pharmaceutical composition of the present invention may be a murine antibody, a chimeric antibody, a humanized antibody, preferably a humanized antibody, which may have SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
- the antibody in the pharmaceutical composition of the present invention has a heavy chain variable region as shown in SEQ ID NO: 7 and a light chain variable region as shown in SEQ ID NO: 8; or has a variable region as shown in SEQ ID NO: respectively.
- the antibody in the pharmaceutical composition of the present invention has a heavy chain amino acid sequence as shown in SEQ ID NO: 11 and a light chain amino acid sequence as shown in SEQ ID NO: 12, respectively.
- the concentration of the anti-BTLA antibody or antigen-binding fragment thereof is about 1-200 mg/mL, preferably about 5-100 mg/mL, preferably about 10-50 mg/mL, more preferably 15-25 mg/mL .
- the concentration of anti-BTLA antibody or its antigen-binding fragment is about 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 35 mg/mL, 40 mg/mL, 45 mg/mL or 50mg/mL; preferably about 10mg/mL, 20mg/mL or 40mg/mL.
- the buffer in the pharmaceutical composition of the present invention can be selected from acetate buffer, citrate buffer, and histidine buffer to provide the pharmaceutical composition of the present invention with a pH of 5.0 to 6.5, preferably 5.0 to 6.0.
- the pH of the buffer used in the pharmaceutical composition of the present invention may be 5.0-6.5, preferably 5.0-6.0.
- a particularly preferred buffer in the pharmaceutical composition of the present invention is histidine buffer.
- the pH of the histidine buffer used in the present invention is 5.0-6.0, more preferably 5.5 ⁇ 0.3, preferably about 5.5.
- the histidine buffer includes histidine-hydrochloride buffer or histidine-acetate buffer, preferably histidine-hydrochloride buffer. More preferably, the histidine-hydrochloride buffer is composed of histidine and histidine hydrochloride, preferably L-histidine and L-histidine monohydrochloride. In some protocols, the histidine buffer is made of 1-20 mM L-histidine and 1-20 mM L-histidine monohydrochloride.
- the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:1 to 1:4. In some schemes, the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:1. In some schemes, the histidine buffer is composed of histidine and histidine hydrochloride in a molar ratio of 1:3. In some schemes, the histidine preparation is: a histidine buffer with a pH of 5.5 made of 4.5 mM L-histidine and 15.5 mM L-histidine monohydrochloride. In some schemes, the histidine preparation is: a histidine buffer with a pH of 6.0 made of 15 mM histidine and 15 mM histidine hydrochloride.
- the histidine buffer in the pharmaceutical composition of the present invention can be a histidine-acetate buffer, preferably, the molar ratio of the two is 1:1 to 1.5:1, preferably, the pH of such a buffer It is 5.5 ⁇ 0.3, preferably about 5.5.
- this type of buffer contains 15-20 mM histidine and 12-15 mM acetic acid.
- the pharmaceutical composition of the present invention may contain: a histidine-histidine hydrochloride buffer with a pH of 5.0-6.0, and a concentration of 10-30 mM in the pharmaceutical composition; and 15-25 mg/mL
- a histidine-histidine hydrochloride buffer with a pH of 5.0-6.0, and a concentration of 10-30 mM in the pharmaceutical composition and 15-25 mg/mL
- the anti-BTLA antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, especially hu17, hu18 or hu19 or the antigen-binding fragment thereof described herein.
- the pharmaceutical composition of the present invention also contains a stabilizer.
- the stabilizer is selected from one or more of sodium chloride, mannitol, sorbitol, sucrose, maltose, xylitol and trehalose.
- the stabilizer in the pharmaceutical composition contains at least sodium chloride, and optionally contains one or more of mannitol, sorbitol, sucrose and trehalose.
- the pharmaceutical composition may contain sodium chloride and mannitol, sodium chloride and sorbitol, sodium chloride and sucrose, or sodium chloride and trehalose.
- the concentration of the stabilizer in the pharmaceutical composition is about 20 mM to 300 mM, preferably 50 mM to 300 mM, more preferably 120 mM to 250 mM.
- the stabilizer is sodium chloride at a concentration of about 50-200 mM; or the stabilizer is mannitol at a concentration of about 100-300 mM; or the stabilizer is sorbitol at a concentration of about 100-300 mM; or The stabilizer is sucrose with a concentration of about 100-300mM; or the stabilizer is trehalose with a concentration of about 100-300mM; or the stabilizer is a combination of about 30-100mM sodium chloride and about 50-200mM mannitol.
- the stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM sorbitol; the stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM sucrose; The stabilizer is a combination of about 30-100 mM sodium chloride and about 50-200 mM trehalose.
- the pharmaceutical composition of the present invention contains: a histidine-histidine hydrochloride buffer with a pH of 5.0-6.0, the concentration of which in the pharmaceutical composition is 10-30 mM; 15- 25mg/mL of the anti-BTLA antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, especially hu17, hu18 or hu19 or antigen-binding fragment thereof as described herein; and a stabilizer of 20mM-300mM, preferably,
- the stabilizer includes at least sodium chloride, optionally including one of mannitol, sorbitol, sucrose and trehalose, preferably 50-150mM sodium chloride, or 40-80mM sodium chloride and 120-150mM Mannitol, or 40-80mM sodium chloride and 120-150mM sorbitol, or 40-80mM sodium chloride and 120-150mM sucrose, or 40-80mM sodium chloride and 120-150mM sucrose, or 40
- the pharmaceutical composition of the present invention also includes a surfactant.
- Preferred surfactants are selected from polysorbate 80, polysorbate 20 and poloxamer 188.
- the most preferred surfactant is polysorbate 80.
- the concentration of the surfactant in the pharmaceutical composition of the present invention is about 0.001%-0.1%, preferably about 0.01%-0.05%, preferably about 0.02%-0.04%.
- the concentration of the surfactant in the pharmaceutical composition of the present invention is about 0.02%, 0.03% or 0.04%, preferably 0.02%.
- the pharmaceutical composition of the present invention contains: a histidine-histidine hydrochloride buffer with a pH of 5.0-6.0, the concentration of which in the pharmaceutical composition is 10-30 mM; 15- 25mg/mL of the anti-BTLA antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, especially hu17, hu18 or hu19 or antigen-binding fragment thereof as described herein; a stabilizer of 20mM-300mM, preferably, the The stabilizer is trehalose, or at least sodium chloride, optionally including one of mannitol, sorbitol, sucrose and trehalose, preferably 200-300mM trehalose, or 50-150mM sodium chloride, or 40-80mM sodium chloride and 120-150mM mannitol, or 40-80mM sodium chloride and 120-150mM sorbitol, or 40-80mM sodium chloride and 120-150mM sucitol, or 40
- the pharmaceutical composition of the present invention contains or consists of the following components: a histidine-histidine hydrochloride buffer with a pH of 5.5 ⁇ 0.3, and a concentration of 20 ⁇ 5mM; 40-80mM sodium chloride; 120-150mM trehalose, 0.02-0.04% polysorbate 80 in w/v; 15-25mg/mL antibody hu18 or its antigen-binding fragment.
- the pharmaceutical composition of the present invention may be a liquid preparation or a lyophilized preparation. It should be understood that for liquid preparations, in addition to the buffers, stabilizers, antibodies or antigen-binding fragments thereof, and surfactants described herein, they also contain water for formulating the pharmaceutical composition.
- the present invention also provides a pharmaceutical composition according to any embodiment of the present invention for the treatment or prevention of BTLA-mediated diseases.
- the pharmaceutical composition according to any embodiment of the present invention is used to treat or prevent BTLA-mediated diseases.
- BTLA-mediated diseases refer to diseases that participate in the occurrence and development of diseases in BTLA, including but not limited to tumors, infectious diseases, and inflammatory or autoimmune diseases.
- tumors suitable for the treatment and prevention of the pharmaceutical composition of the present invention include melanoma, breast cancer, kidney cancer, prostate cancer, colon cancer, lung cancer, pancreatic cancer, bone cancer, skin cancer, head or neck cancer, and uterine cancer.
- Cancer ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, esophageal cancer, small intestine cancer, cervical cancer, vaginal cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, endocrine system cancer, Thyroid cancer, adrenal glands, soft tissue cancer, urethral cancer, chronic or acute leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, Renal or ureteral cancer, renal pelvis cancer, central nervous system neoplasms, primary central nervous system lymphoma, tumor angiogenesis, spinal cord axis tumors, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid Carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancer
- Autoimmune diseases suitable for the treatment and prevention of the pharmaceutical composition of the present invention include organ-specific autoimmune diseases and systemic autoimmune diseases;
- the organ-specific autoimmune diseases include chronic lymphocytic thyroiditis, hyperthyroidism, Insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, pulmonary hemorrhage nephritis syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple cerebral spinal cord Sclerosis, acute idiopathic polyneuritis, etc.
- the systemic autoimmune diseases include systemic lupus erythematosus, wet arthritis, systemic vasculitis, scleroderma, gastric sores, dermatomyositis, mixed Connective tissue disease, autoimmune hemolytic anemia, ulcerative colitis, etc.
- the buffer system and pH closely affect the stability of the antibody, and each antibody with unique physical and chemical properties has the most suitable buffer type and pH.
- This example aims to screen an optimal buffer system and pH, so that the anti-BTLA antibody disclosed in the present invention has the best stability for clinical application.
- This example was performed with antibody hu18 at concentrations of approximately 10 mg/mL, 20 mg/mL, and 40 mg/mL.
- the sample was concentrated and exchanged by ultrafiltration using VIVAFlow200. After the liquid exchange, the sample was in the corresponding prescription, and the sample was placed in a closed centrifuge tube for buffer screening. Screened acetate buffer, citrate buffer and histidine buffer, pH from 5.0 to 6.5 (as shown in Table 1). The samples were placed in a 40°C environment, and were taken out for analysis and testing in the 0th week, the 2nd week, and the 4th week.
- the main pathway of protein degradation is the formation of aggregates, lysate products and charged variants.
- SEC-HPLC Size exclusion chromatography
- CEX-HPLC cation exchange chromatography
- a histidine buffer with a protein concentration of 20 mg/ml and a pH of 5.5 or 6.0 was selected for the prescription screening of excipients (stabilizers).
- Surfactants added to liquid formulations are often used to protect proteins such as antibodies from the stress induced by the air/solution interface and the stress induced by the solution/surface during storage to reduce the aggregation of antibodies or minimize the formation of particulate matter in the formulation.
- Reagent which is conducive to the stability of the physical and chemical properties of the antibody.
- 20mM histidine buffer the molar ratio of histidine to histidine hydrochloride is 1:1, and the pH is 6.0
- the antibody hu18 of 20mg/ml different concentrations of polysorbate 20 are added respectively.
- polysorbate 80 placed at 40°C for 4 weeks and then analyzed and tested. The results are shown in Table 6.
- Liquid pharmaceutical products containing therapeutic antibodies usually need to be stored at 2-8°C, so it is very important for the formulation to maintain high stability during long-term storage. Based on the above screening results, we designed No. 27 prescription on the basis of the previous 26 prescriptions to study the long-term stability of the preparation.
- the histidine buffer is configured with a molar ratio of histidine to histidine hydrochloride of 1:3.
- NA in the table means that it is a non-key inspection item at this point in time, and no test is done at this sampling point, and NR means that it has not arrived at this point in time, the same below.
- prescription No. 27 has higher stability against protein degradation, and the degradation kinetic parameters measured at 25 ⁇ 2° C. meet the requirement of storage at room temperature for up to 12 months.
- NA in the table means that it is a non-key inspection item at this point in time, and no test is done at this sampling point, and NR means that this point in time has not been reached.
- Example 6 ELISA to detect the binding of humanized antibody to hBTLA
- the binding specificity of humanized antibodies hu17, hu18 and hu19 with hBTLA was detected by conventional ELISA detection methods. Coat the 96-well microtiter plate with 0.5 ⁇ g/ml hBTLA and incubate at 37°C for 60 minutes. Then the solution in the well was discarded, washed 3 times with washing buffer, and blocked with PBS solution containing 2% BSA for 60 minutes.
- Table 10 Specific binding data of humanized antibody combination hu17, hu18 and hu19 to hBTLA
- Example 7 FACS detects the binding of humanized antibody to hBTLA on 293F cells
- FACS Cell-based flow cytometry
- the EC 50 value of each antibody is shown in Table 11 below. The results showed that humanized antibodies hu17, hu18, and hu19 can effectively bind to hBTLA on 293F cells.
- Example 8 FACS detection of the blocking effect of humanized antibodies on blocking the binding of BTLA and HVEM
- FACS flow cytometry
- the washed cells were resuspended in a 4°C buffer containing propidium iodide (PI) and 0.02% sodium azide to prevent receptor internalization, and then analyzed by flow cytometry. According to the exclusion of PI-positive cells from the FSC/SSC gate, live cells were gated and their geometric mean fluorescence was measured. The data was analyzed using the S-shaped dose-response model in PrismTM software.
- PI propidium iodide
- the IC 50 value of each antibody is shown in Table 12 below. The results show that humanized antibodies hu17, hu18, and hu19 can effectively block the binding of BTLA to HVEM on the cell surface.
- Example 10 Affinity of humanized anti-BTLA antibody to hBTLA
- the Biacore T200 instrument of GE Healthcare Life Sciences was used for the detection experiment, and the Series S CM5 chip was loaded on the instrument.
- the system buffer used was HBS-EP+ (10mM HEPES, pH 7.4, 150mM NaCl, 3mM EDTA, 0.05% surface activity) Agent P20).
- the antibody was diluted 2-fold with Biacore system buffer (the ingredients in the diluent except for the antibody are the same as the prescription number 27), a total of 6 concentration points.
- the concentration gradients are 24nM, 12nM, 6nM, 3nM, 1.5nM and 0.75nM, of which 24nM is a repeated test.
- the data analysis uses the data analysis software Biacore T200 Evaluation Software version 3.0 of GE Healthcare Life Sciences.
- the data fitting used model is 1:1Binding.
- the kinetic constant binding rate ka (1/Ms), the dissociation rate kd (1/s), and the affinity constant KD (M) of the binding between the antibody and the antigen were obtained by fitting. The results are shown in Table 14.
- Example 11 Characterization of the binding kinetics of humanized antibodies with different species of BTLA
- BTLA human BTLA, cyno BTLA or murine BTLA was coupled to an activated CM5 biosensor chip to achieve approximately 100-200 response units (RU), and then unreacted groups were blocked with IM ethanolamine.
- RU response units
- the RU is used to calculate the combined response of BTLA in different provenances.
- Example 12 Inhibition of humanized antibody (prescription number: 27) on tumor growth in mice
- the MC38-hHVME cell bank was constructed by electrotransformation of Hxp-hHVEM plasmid on mouse colon cancer (MC38) cells (ATCC), and then the cells were subcloned by limiting dilution method, and single clones were screened out by flow cytometry to obtain MC38-HVEM cells ; Then MC38-hHVEM cells were inoculated subcutaneously on the right side of B-hBTLA humanized female mice at a concentration of 1 ⁇ 10 6 cells/0.1 mL, and when the tumor grew to about 118 mm 3 , they were randomly divided into groups according to the tumor volume, 8 in each group There are 5 groups, namely: G1 0.9% sodium chloride injection solvent control group, G2KLH (anti-keyhole limpet hemocyanin antibody) (10mg/kg) negative control group, G3hu18 (1mg/kg) group, G4hu18( 3mg/kg) group and G5hu18 (10mg/kg)
- the route of administration for all groups was intraperitoneal injection, twice a week for 7 consecutive administrations, and the experiment ended 4 days after the last administration.
- the tumor volume and body weight were measured twice a week, and the mouse body weight and tumor volume were recorded.
- Table 15 and Figure 2 show the effect of each group of test products on the tumor volume of MC38-hHVEM cell transplantation in B-hBTLA mice.
- 21 days after the first administration the average tumor volume of the KLH (10mg/kg) negative control group was 1560 ⁇ 256mm 3 , and the average tumor volume of the other administration groups were 1073 ⁇ 224mm 3 , 747 ⁇ 268mm 3 and 868 ⁇ 211mm 3, respectively .
- the TGI% of each administration group were 33.7%, 56.4%, and 48.0%, and the P values were 0.175, 0.046, and 0.056, indicating that the tested drug hu18 had a certain inhibitory effect on tumor growth.
- a mean ⁇ standard error
- b the tumor volume of the treatment group and the tumor volume of the KLH negative control group are statistically compared 21 days after the treatment, t-test.
- Table 16 and Figure 3 show the effect of each group of test products on the body weight of MC38-hHVEM cell transplantation B-hBTLA mice. All the experimental animals were in good activity and eating state during the administration period, and the body weight of the animals in each administration group increased to a certain extent. There was no death of experimental animals during the experiment. 21 days after the administration, compared with the weight of the mice in the KLH negative control group, there was no significant change in the body weight of the mice in each administration group (P>0.05), indicating that the experimental animals had a good tolerance to the test product.
- Table 16 Effect of the test substance on the body weight of MC38-hHVEM cells transplanted in B-hBTLA mice
- a Mean ⁇ standard error
- b The weight of the administration group and the weight of the KLH negative control group are statistically compared 21 days after administration, t-test.
- Example 13 Humanized antibody hu18 (prescription number: 27) has no ADCC effector function
- ADCC is initiated when the antibody binds to the target protein on the cell surface and then to the Fc ⁇ receptor (Fc ⁇ R) expressed on the effector cell.
- Fc ⁇ R Fc ⁇ receptor
- human IgG1 has a significantly higher binding affinity to Fc ⁇ R than IgG4, especially binding to Fc ⁇ R-I and Fc ⁇ R-IIIA, and this affinity is correlated with the strength of IgG1 to activate ADCC.
- Reminiscent of ADCC CDC is activated when antibodies cross-link cell surface targets and C1q proteins, followed by a cascade of complement complex formation and target cell lysis.
- the detection of antibody binding to Fc ⁇ R and C1q can serve as a basic indicator of ADCC and CDC. Therefore, the present invention uses biacore T200 (GE) to evaluate the kinetic affinity of the monoclonal antibody to the main Fc ⁇ R binding.
- GE biacore T200
- GE's anti-His antibody is immobilized on the sensor chip.
- Various Fc receptors including recombinant human Fc ⁇ RIIIA (CD16a) V176, recombinant human Fc ⁇ RIIA (CD32a) R167, recombinant human Fc ⁇ RI (CD64) and recombinant human FcRn were captured, and then injected a series of diluted recombinant human anti-BTLA antibodies (ie hu18), to detect and analyze the binding properties of the interaction.
- hu18 is an IgG4 subtype antibody
- hu18-IgG1 is an IgG1 subtype, which shares the same Fab with hu18 and serves as a positive control.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
人源化抗体 | hu17 | hu18 | hu19 |
EC 50(ng/mL) | 6.3 | 5.4 | 6.6 |
hu17 | hu18 | hu19 | |
EC 50(ng/mL) | 96.74 | 89.34 | 95.06 |
hu17 | hu18 | hu19 | |
IC 50(ng/mL) | 142.7 | 172.2 | 161.5 |
hu17 | hu18 | hu19 | |
EC 50(ng/mL) | 256.7 | 277.3 | 290.4 |
ka(1/Ms) | kd(1/s) | KD(M) | |
hu17 | 6.24E+05 | 1.16E-04 | 1.86E-10 |
hu18 | 6.39E+05 | 8.67E-05 | 1.36E-10 |
Claims (13)
- 一种药物组合物,包含:(1)缓冲液;和(2)抗BTLA抗体或其抗原结合片段,其中所述抗BTLA抗体或其抗原结合片段具有氨基酸序列分别如SEQ ID NO:1、SEQ ID NO:2和SEQ ID NO:3所示的HCDR1、HCDR2和HCDR3,和氨基酸序列分别如SEQ ID NO:4、SEQ ID NO:5和SEQ ID NO:6所示的LCDR1、LCDR2和LCDR3。
- 如权利要求1所述的药物组合物,其中所述缓冲液选自醋酸缓冲液、柠檬酸缓冲液和组氨酸缓冲液;优选地,所述缓冲液为组氨酸缓冲液;更优选地,所述缓冲液为组氨酸-盐酸盐缓冲液,更优选为组氨酸-组氨酸盐酸盐缓冲液。
- 如权利要求2所述的药物组合物,其中所述缓冲液的浓度约为10~30mM;优选地,所述缓冲液的pH约为5.0-6.5,优选约为5.0-6.0。
- 如权利要求1-3任一项所述的药物组合物,其中所述药物组合物还包括稳定剂,所述稳定剂选自氯化钠、甘露醇、山梨醇、蔗糖、麦芽糖、木糖醇和海藻糖中的一种或两种以上;优选地,所述稳定剂为海藻糖和氯化钠的组合。
- 如权利要求4所述的药物组合物,其中所述稳定剂为浓度约50-200mM的氯化钠;或所述稳定剂为浓度约100-300mM的甘露醇;或所述稳定剂为浓度约100-300mM的山梨醇;或所述稳定剂为浓度约100-300mM的蔗糖;或所述稳定剂为浓度约100-300mM的海藻糖;或所述稳定剂为约30-100mM的氯化钠与约50-200mM的甘露醇的组合;或所述稳定剂为约30-100mM的氯化钠与约50-200mM的山梨醇的组合;或所述稳定剂为约30-100mM的氯化钠与约50-200mM的蔗糖的组合;或所述稳定剂为约30-100mM的氯化钠与约50-200mM的海藻糖的组合;优选地,所述稳定剂为约30-100mM的氯化钠与约50-200mM的海藻糖的组合。
- 如权利要求1-5任一项所述的药物组合物,其中所述药物组合物还包括表面活性剂,所述表面活性剂选自聚山梨醇酯80、聚山梨醇酯20或泊洛沙姆188,优选地,所述表面活性剂为聚山梨醇酯80。
- 如权利要求6所述的药物组合物,其中所述表面活性剂浓度约为0.01%-0.1%;优选地,所述表面活性剂浓度约为0.01%-0.05%。
- 如权利要求1-7任一项所述的药物组合物,其中所述抗BTLA抗体具有如氨基酸序列SEQ ID NO:7所示的重链可变区,和氨基酸序列如SEQ ID NO:8所示的轻链可变区;或具有氨基酸序列如SEQ ID NO:7所示的重链可变区,和氨基酸序列如SEQ ID NO:9所示的轻链可变区;或具有氨基酸序列如SEQ ID NO:7所示的重链可变区,和氨基酸序列如SEQ ID NO:10所示的轻链可变区。
- 如权利要求1-7任一项所述的药物组合物,其中所述抗BTLA抗体具有如SEQ ID NO:11所示的重链氨基酸序列和如SEQ ID NO:12所示的轻链氨基酸序列。
- 如权利要求1-9任一项所述的药物组合物,其中所述抗BTLA抗体或其抗原结合片段浓度约为5-100mg/mL,优选约为10-50mg/mL,更优选15-25mg/mL。
- 如权利要求1-9任一项所述的药物组合物,其包含如下(1)-(13)任一项所示的组分,或由如下(1)-(13)任一项所示的组分组成:(1)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM组氨酸缓冲液,pH约为5.0-6.0;(c)约30mM至约100mM的氯化钠与约50-200mM的海藻糖的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(2)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM组氨酸缓冲液,pH约为5.0-6.0;(c)约30mM至约100mM的氯化钠与约50-200mM的甘露醇的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(3)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM组氨酸缓冲液,pH约为5.0-6.0;(c)约30mM至约100mM的氯化钠与约50-200mM的蔗糖的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(4)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM组氨酸缓冲液,pH约为5.0-6.0;(c)约30mM至约100mM的氯化钠与约50-200mM的山梨醇的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(5)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM组氨酸缓冲液,pH约为5.0-6.0;(c)约100mM至约300mM的海藻糖;(d)以及约0.01%-0.05%的聚山梨醇酯80;(6)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM柠檬酸缓冲液,pH约为5.5-6.5;(c)约100mM至约300mM的海藻糖;(d)以及约0.01%-0.05%的聚山梨醇酯80;(7)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM柠檬酸缓冲液,pH约为5.5-6.5;(c)约30mM至约100mM的氯化钠与约50-200mM的甘露醇的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(8)(a)约10mg/mL-50mg/mL的抗BTLA抗体或其抗原结合片段;(b)约10-30mM醋酸缓冲液,pH约为5.0-6.0;(c)约30mM至约100mM的氯化钠与约50-200mM的甘露醇的组合;(d)以及约0.01%-0.05%的聚山梨醇酯80;(9)(a)约20mg/mL的抗BTLA抗体或其抗原结合片段;(b)约20mM组氨酸缓冲液,pH约为6.0;(c)约54mM的氯化钠与约132mM的海藻糖的组合;(d)以及约0.02%的聚山梨醇酯80;(10)(a)约20mg/mL的抗BTLA抗体或其抗原结合片段;(b)约20mM组氨酸缓冲液,pH约为5.5;(c)约220mM的海藻糖的组合;(d)以及约0.02%的聚山梨醇酯80;(11)(a)约20mg/mL的抗BTLA抗体或其抗原结合片段;(b)约20mM组氨酸缓冲液,pH约为5.5;(c)约50mM的氯化钠与约140mM的甘露醇的组合;(d)以及约0.02%的聚山梨醇酯80;(12)(a)约20mg/mL的抗BTLA抗体或其抗原结合片段;(b)约20mM组氨酸缓冲液,pH约为5.5;(c)约50mM的氯化钠与约140mM的海藻糖的组合;(d)以及约0.02%的聚山梨醇酯80;和(13)(a)约20mg/mL的抗BTLA抗体或其抗原结合片段;(b)约20mM组氨酸缓冲液,pH约为5.0-6.0;(c)约50mM的氯化钠与约140mM的海藻糖的组合;(d)以及约0.02%的聚山梨醇酯80。
- 如权利要求1所述的药物组合物,其特征在于,所述药物组合物含有以下组分,或由以下组分组成:pH为5.5±0.3的组氨酸-组氨酸盐酸盐缓冲液,其浓度为20±5mM;40-80mM的氯化钠;120-150mM的海藻糖;以w/v计0.02-0.04%的聚山梨酯80;15-25mg/mL的抗BTLA抗体或其抗原结合片段,其中,所述抗BTLA抗体具有如SEQ ID NO:11所示的重链氨基酸序列和如SEQ ID NO:12所示的轻链氨基酸序列。
- 如权利要求1-12任一项所述的药物组合物在制备治疗或预防BTLA介导的疾病的药物中的用途;优选地,所述疾病为肿瘤、感染性疾病或自身免疫性疾病; 优选地,所述肿瘤包括黑色素瘤、乳腺癌、肾癌、前列腺癌、结肠癌、肺癌、胰腺癌、骨癌、皮肤癌、头或颈癌、子宫癌、卵巢癌、直肠癌、肛区癌、胃癌、睾丸癌、食道癌、小肠癌、宫颈癌、阴道癌、何杰金氏病、非何杰金氏淋巴瘤、食道癌、内分泌系统癌、甲状腺癌、肾上腺爱、软组织癌、尿道癌、慢性或急性白血病、慢性髓细胞样白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病、儿童期实体瘤、淋巴细胞性淋巴瘤、膀胱癌、肾或输尿管癌、肾盂癌、中枢神经系统的赘生物、原发性中枢神经系统淋巴瘤、肿瘤血管发生、脊髓轴肿瘤、脑干胶质瘤、垂体腺瘤、卡波西氏肉瘤、表皮样癌、鳞状细胞癌、T细胞淋巴瘤、环境诱发的癌症;所述自身免疫性疾病包括器官特异性自身免疫病和系统性自身免疫病,其中,所述器官特异性自身免疫病包括慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎,所述系统性自身免疫病包括系统性红斑狼疮、类分湿关节炎、系统性血管炎、硬皮病、天胞疮、皮肌炎、混合性结缔组织病、自身免疫性溶血性贫血和溃疡性结肠炎。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21744312.6A EP4095158A4 (en) | 2020-01-20 | 2021-01-19 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-BTLA ANTIBODIES AND USE THEREOF |
CN202180009885.XA CN114981307A (zh) | 2020-01-20 | 2021-01-19 | 抗btla抗体药物组合物及其用途 |
CA3165369A CA3165369A1 (en) | 2020-01-20 | 2021-01-19 | Anti-btla antibody pharmaceutical composition and use thereof |
BR112022013292A BR112022013292A2 (pt) | 2020-01-20 | 2021-01-19 | Composição farmacêutica contendo anticorpo anti-btla e uso da mesma |
JP2022543548A JP2023510928A (ja) | 2020-01-20 | 2021-01-19 | 抗btla抗体医薬組成物及びその使用 |
KR1020227026032A KR20220129564A (ko) | 2020-01-20 | 2021-01-19 | 항 btla 항체 약학적 조성물 및 그의 용도 |
AU2021211795A AU2021211795A1 (en) | 2020-01-20 | 2021-01-19 | Pharmaceutical composition containing anti-BTLA antibody and use thereof |
US17/866,867 US20230192854A1 (en) | 2020-01-20 | 2022-07-18 | Anti-btla antibody pharmaceutical composition and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010066932.1 | 2020-01-20 | ||
CN202010066932.1A CN113134081A (zh) | 2020-01-20 | 2020-01-20 | 抗btla抗体药物组合物及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/866,867 Continuation-In-Part US20230192854A1 (en) | 2020-01-20 | 2022-07-18 | Anti-btla antibody pharmaceutical composition and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021147846A1 true WO2021147846A1 (zh) | 2021-07-29 |
Family
ID=76809158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/072660 WO2021147846A1 (zh) | 2020-01-20 | 2021-01-19 | 抗btla抗体药物组合物及其用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230192854A1 (zh) |
EP (1) | EP4095158A4 (zh) |
JP (1) | JP2023510928A (zh) |
KR (1) | KR20220129564A (zh) |
CN (2) | CN113134081A (zh) |
AU (1) | AU2021211795A1 (zh) |
BR (1) | BR112022013292A2 (zh) |
CA (1) | CA3165369A1 (zh) |
WO (1) | WO2021147846A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023125483A1 (zh) * | 2021-12-28 | 2023-07-06 | 山东先声生物制药有限公司 | 一种抗tnfr2抗体药物组合物 |
WO2023199224A1 (en) | 2022-04-12 | 2023-10-19 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and methods for treating solid tumors with anti-btla as mono or combination therapy |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117693362A (zh) * | 2021-08-02 | 2024-03-12 | 甘李药业股份有限公司 | 含有抗il-4r抗体的稳定制剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110230647A1 (en) * | 2002-06-20 | 2011-09-22 | The Washington University | Compositions and methods for modulating lymphocyte activity |
CN102762593A (zh) * | 2009-07-31 | 2012-10-31 | 米德列斯公司 | 抗btla的完全人抗体 |
CN108699154A (zh) * | 2016-02-26 | 2018-10-23 | 国家医疗保健研究所 | 对btla具有特异性的抗体及其用途 |
CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
-
2020
- 2020-01-20 CN CN202010066932.1A patent/CN113134081A/zh active Pending
-
2021
- 2021-01-19 BR BR112022013292A patent/BR112022013292A2/pt unknown
- 2021-01-19 AU AU2021211795A patent/AU2021211795A1/en active Pending
- 2021-01-19 CN CN202180009885.XA patent/CN114981307A/zh active Pending
- 2021-01-19 EP EP21744312.6A patent/EP4095158A4/en active Pending
- 2021-01-19 JP JP2022543548A patent/JP2023510928A/ja active Pending
- 2021-01-19 KR KR1020227026032A patent/KR20220129564A/ko active Search and Examination
- 2021-01-19 CA CA3165369A patent/CA3165369A1/en active Pending
- 2021-01-19 WO PCT/CN2021/072660 patent/WO2021147846A1/zh unknown
-
2022
- 2022-07-18 US US17/866,867 patent/US20230192854A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110230647A1 (en) * | 2002-06-20 | 2011-09-22 | The Washington University | Compositions and methods for modulating lymphocyte activity |
CN102762593A (zh) * | 2009-07-31 | 2012-10-31 | 米德列斯公司 | 抗btla的完全人抗体 |
CN108699154A (zh) * | 2016-02-26 | 2018-10-23 | 国家医疗保健研究所 | 对btla具有特异性的抗体及其用途 |
CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
Non-Patent Citations (22)
Title |
---|
"Peptide and Protein Drug Delivery", 1991, MARCEL DEKKER, INC., pages: 247 - 301 |
ABBAS ET AL., NAT.MED., vol. 5, 1999, pages 1345 - 6 |
AL-LAZIKANI ET AL.: "Standard conformations for the canonical structures of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 273, 1997, pages 927 - 948, XP004461383, DOI: 10.1006/jmbi.1997.1354 |
CARRENO ET AL., ANNU. REV. IMMUNOL., vol. 20, 2002, pages 29 - 53 |
CHAMBERS ET AL., ANN. REV. IMMUNOL., vol. 19, 2001, pages 565 - 594 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883 |
COYLE ET AL., NAT. IMMUNOL., vol. 2, 2001, pages 203 - 9 |
EGEN ET AL., NATURE IMMUNOL, vol. 3, 2002, pages 611 - 618 |
GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4181 |
HODGSON, BIOTECHNOLOGY (NY, vol. 9, 1991, pages 421 - 5 |
JI RONG 、 、, JIANG TAO, LI YEPENG: "Study on the thermal stabilization of monoclonal antibody by trehalose", CHINESE JOURNAL OF FOOD HYGIENE, SCHOOL OF CHINESE MATERIA MEDICA, GUANGZHOU UNIVERSITY OF CHINESE MEDICINE, GUANGZHOU, CHINA, CN, vol. 13, no. 2, 30 March 2001 (2001-03-30), CN, pages 10 - 12, XP055832534, ISSN: 1004-8456 * |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 |
JONES, A., ADV. DRUG DELIVERY REV., vol. 10, 1993, pages 29 - 90 |
KABAT ET AL., J. IMMUNOL., vol. 147, 1991, pages 1709 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES |
LIANG ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 384 - 90 |
LIU ET AL., PROC.NATL.ACAD.SCI. USA, vol. 84, 1987, pages 3439 - 43 |
NUCLEIC ACIDS RESEARCH, vol. 27, 1999, pages 209 - 212 |
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 |
See also references of EP4095158A4 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 |
WANG X-F ET AL: "Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells.", TISSUE ANTIGENS., MUNKSGAARD, COPENHAGEN., DK, vol. 69, no. 2, 1 February 2007 (2007-02-01), DK, pages 145 - 153, XP002441883, ISSN: 0001-2815, DOI: 10.1111/j.1399-0039.2006.00710.x * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023125483A1 (zh) * | 2021-12-28 | 2023-07-06 | 山东先声生物制药有限公司 | 一种抗tnfr2抗体药物组合物 |
WO2023199224A1 (en) | 2022-04-12 | 2023-10-19 | Shanghai Junshi Biosciences Co., Ltd. | Compositions and methods for treating solid tumors with anti-btla as mono or combination therapy |
Also Published As
Publication number | Publication date |
---|---|
CN113134081A (zh) | 2021-07-20 |
KR20220129564A (ko) | 2022-09-23 |
JP2023510928A (ja) | 2023-03-15 |
US20230192854A1 (en) | 2023-06-22 |
AU2021211795A1 (en) | 2022-09-15 |
CN114981307A (zh) | 2022-08-30 |
EP4095158A4 (en) | 2024-03-20 |
BR112022013292A2 (pt) | 2022-09-06 |
CA3165369A1 (en) | 2021-07-29 |
EP4095158A1 (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108137687B (zh) | 抗ox40抗体及其用途 | |
JP6900323B2 (ja) | 抗ctla−4抗体およびその使用方法 | |
US20190016814A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
WO2021147846A1 (zh) | 抗btla抗体药物组合物及其用途 | |
TW201902915A (zh) | 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途 | |
KR20190137850A (ko) | 항-icos 효능제 항체 및 그의 용도 | |
JP2020504171A (ja) | 抗PD−1抗体との組み合わせのための抗Tim−3抗体 | |
WO2021083271A1 (zh) | 含有抗pd-l1抗体的稳定制剂 | |
CN113150144A (zh) | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 | |
CN110546163A (zh) | 抗-tigit抗原结合蛋白及其使用方法 | |
JP2021519594A (ja) | 抗trem−1抗体およびその使用 | |
CN113272017A (zh) | 抗tim-3抗体 | |
AU2017362721A1 (en) | Anti-GITR antigen-binding proteins and methods of use thereof | |
WO2021063352A1 (zh) | 一种抗pd-l1抗原结合蛋白及其应用 | |
CN108948193B (zh) | 针对tim-3的抗体分子,抗原结合片段及其医药用途 | |
EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
CA2874918A1 (en) | Tlr3 binding agents | |
JP2020536495A (ja) | 抗lag−3抗体及びその使用 | |
CA2824313A1 (en) | Tlr3 binding agents | |
CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
WO2019174637A1 (zh) | 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途 | |
KR20210131312A (ko) | 인간 cd137에 결합하는 항체의 제제 및 이의 용도 | |
WO2018059465A1 (zh) | 抗cd27抗体、其抗原结合片段及其医药用途 | |
WO2023134771A1 (zh) | 抗ctla-4抗体药物组合物及其用途 | |
CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21744312 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022013292 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022543548 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3165369 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021744312 Country of ref document: EP Effective date: 20220822 |
|
ENP | Entry into the national phase |
Ref document number: 112022013292 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220701 |
|
ENP | Entry into the national phase |
Ref document number: 2021211795 Country of ref document: AU Date of ref document: 20210119 Kind code of ref document: A |